Journal Mobile Options
Table of Contents
Vol. 47, No. 2, 2003
Issue release date: April 2003
Neuropsychobiology 2003;47:102–108

Endocrine and Cardiovascular Responses to Corticotropin-Releasing Hormone in Patients with Posttraumatic Stress Disorder: A Role for Atrial Natriuretic Peptide?

Kellner M. · Yassouridis A. · Hübner R. · Baker D.G. · Wiedemann K.
aDepartment of Psychiatry and Psychotherapy, University Hospital Hamburg-Eppendorf, Hamburg, bMax Planck Institute of Psychiatry, Clinical Institute, Munich, Germany; cDepartment of Psychiatry, University of Cincinnati and Cincinnati VA Medical Center, Cincinnati, Ohio, USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Hypothalamic-pituitary-adrenocortical (HPA) axis data, such as low plasma cortisol concentrations in spite of increased corticotropin-releasing hormone (CRH) levels in patients with posttraumatic stress disorder (PTSD), are difficult to interpret. Atrial natriuretic peptide (ANP) may be an explanatory link in the neuroendocrine pathophysiology of the disorder, since it is a neuromodulator with antianxiety effects that inhibits HPA activity at multiple levels. Seventeen patients with chronic PTSD and 17 healthy control subjects were given 100 µg of human CRH at 3 p.m. ANP, adrenocorticotropic hormone (ACTH), and cortisol levels in plasma as well as blood pressure and heart rate were measured during basal conditions and after CRH stimulation. Basal ANP levels were significantly lower in PTSD patients in comparison with normal controls, but the response to CRH was undistinguishable. In contrast to our expectation, no significant differences in basal or CRH-stimulated ACTH or cortisol parameters could be observed. Systolic and diastolic blood pressures at baseline and after CRH were significantly elevated in PTSD patients. All group differences remained significant after controlling for basal blood pressure and/or body mass index. Our data do not support a role of ANP in abnormal HPA axis regulation in PTSD. However, the persistently low ANP plasma levels in PTSD patients despite elevated blood pressure may serve to facilitate anxiety behavior and have adverse long-term cardiovascular consequences. Further studies to assess ANP secretion in PTSD patients and to clarify its pathophysiological impact are needed.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Aguilera G, Rabadan-Diehl C, Nikodemova M: Regulation of pituitary corticotropin-releasing hormone receptors. Peptides 2001;22:769–774.
  2. Koob GF: Corticotropin-releasing factor, norepinephrine, and stress. Biol Psychiatry 1999;46:1167–1180.
  3. Arborelius L, Owens JM, Plotzky PM, Nemeroff CB: The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 1999;160:1–12.
  4. Holsboer F: The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res 1999;33:181–214.
  5. Bremner JD, Licinio J, Darnell A, Krystal JH, Owens MJ, Southwick SM, Nemeroff CB, Charney DS: Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry 1997;154:624–629.
  6. Baker DG, West SA, Nicholson WE, Ekhator, NN, Kasckow JW, Hill KK, Bruce AB, Orth DN, Geracioti TD Jr: Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am J Psychiatry 1999:156:585–588.
  7. Kellner M, Yehuda R: Do panic and posttraumatic stress disorder share a common psychoneuroendocrinology? Psychoneuroendocrinology 1999;24:485–504.
  8. Kaskow JW, Baker D, Geracioti TD Jr: Corticotropin-releasing hormone in depression and post-traumatic stress disorder. Peptides 2001;22:845–851.
  9. Kalin NH, Shelton SE, Barksdale CM, Brownfield MS: A diurnal rhythm in cerebrospinal fluid corticotrophin-releasing hormone different from the rhythm of pituitary-adrenal activity. Brain Res 1987;426:385–391.
  10. Kling MA, DeBellis MD, O’Rourke DK, Listwak SJ, Geracioti TD Jr, McCucheon IE, Kalogeras KT, Oldfield EH, Gold PW: Diurnal variation of cerebrospinal fluid immunoreactive corticotropin-releasing hormone levels in healthy volunteers. J Clin Endocrinol Metab 1994;79:233–239.
  11. Smith MA, Davidson J, Ritchie JC, Kudler H, Lipper S, Chappell P, Nemeroff CB: The corticotrophin-releasing hormone test in patients with posttraumatic stress disorder. Biol Psychiatry 1989;26:349–355.
  12. Kellner M, Wiedemann K, Yassouridis A, Levengood R, Guo LS, Holsboer F, Yehuda R: Behavioral and endocrine response to cholecystokinin tetrapeptide in patients with posttraumatic stress disorder. Biol Psychiatry 2000;47:107–111.
  13. Rasmusson AM, Lipschitz DS, Wang S, Hu S, Vojvoda D, Bremner JD, Southwick SM, Charney DS: Increased pituitary and adrenal reactivity in premenopausal women with PTSD. Biol Psychiatry 2001;50:965–977.
  14. Wiedemann K, Jahn H, Kellner M: Effects of natriuretic peptides upon hypothalamo-pituitary-adrenocortical system activity and anxiety behaviour. Exp Clin Endocrinol Diabetes 2000;108:5–13.
  15. Imura H, Nakao K, Itoh H: The natriuretic peptide system in the brain: Implications in the central control of cardiovascular and neuroendocrine functions. Front Neuroendocrinol 1992;13:217–249.
  16. Kellner M, Wiedemann K, Holsboer F: Atrial natriuretic peptide inhibits the CRH-stimulated secretion of ACTH and cortisol in man. Life Sci 1992;50:1835–1842.
  17. Bierwolf C, Burgemeister A, Luthke K, Born J, Fehm HL: The influence of exogenous atrial natriuretic peptide on the pituitary-adrenal response to corticotropin-releasing hormone and vasopressin in healthy men. J Clin Endocrinol Metab 1998;83:1151–1157.
  18. Vesely DL, San Miguel GI, Hassan I, Schocken DD: Atrial natriuretic hormone, vessel dilatator, long-acting natriuretic hormone, and kaliuretic hormone decrease the circulating concentrations of CRH, corticotropin, and cortisol. J Clin Endocrinol Metab 2001;86:4244–4249.
  19. Tojo K, Sato S, Tokudome G, Ohta M, Kawaguchi Y, Sakai O, Nakagawa O, Nakao K: Stimulation by corticotropin-releasing factor of atrial natriuretic peptide and brain natriuretic peptide secretions from cultured neonatal rat cardiocytes. Biochem Biophys Res Commun 1996;225:340–346.
  20. Colao A, Pivonello R, Ferone D, Faggiano A, Facciolli G, Di Somma C, Boudouresque F, Oliver C, Lombardi G: Effect of corticotropin-releasing hormone on arginine vasopressin and atrial natriuretic factor in patients with Cushing’s disease. Clin Endocrinol (Oxf) 1998;49:77–84.
  21. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for the DSM-IV Axis I Disorders. New York, Biometrics Research Department, New York State Psychiatric Institute, 1995.
  22. Foa EB, Cashman L, Jaycox L, Perry K: The validation of a self-report measure of posttraumatic stress disorder: The Posttraumatic Diagnostic Scale. Psychol Assess 1997;4:445–451.

    External Resources

  23. Beck AT, Ward CH, Mendelsohn M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–571.
  24. Onat A, Sansoy V: Systolic and diastolic blood pressure related to six other risk parameters in Turkish adults: Strong correlation with relative weight. Int J Cardiol 1998;63:295–303.
  25. Mahanonda N, Bhuripanyo K, Leowattana W, Kangkagate C, Chotinaiwattarakul C, Pornratanarangsi S, Samranthin M: Obesity and risk factors of coronary heart disease in healthy Thais: A cross-sectional study. J Med Assoc Thai 2000;83 suppl 2:S35–S45.
  26. Kopelman PG, Grossman A, Lavander P, Besser GM, Rees LH, Coy D: The cortisol response to corticotropin-releasing factor is blunted in obesity. Clin Endocrinol 1988;28:15–18.
  27. Kornel L, Miyabo S, Saito Z, Cha R-W, Wu F-T: Corticosteroids in human blood. 8. Cortisol metabolites in plasma of normotensive subjects and patients with essential hypertension. J Clin Endocrinol Metab 1975;40:949–958.
  28. Sakamoto M, Tanaka I, Oki Y, Ikeda Y, Nanno M, Yoshimi T: Atrial natriuretic peptide and vasopressin in human plasma. Peptides 1988;9:187–191.
  29. Taylor MA, Ragsdale NV, Ayers CR, Gear AR: Atrial natriuretic factor in essential hypertension. Life Sci 1989;44:603–610.
  30. Baranowska B, Gutkowska J, Talbot P, Genest J, Cantin M: Plasma immunoreactive atrial natriuretic factor is inhibited by selective blockade of α2-adrenergic receptors in conscious Sprague-Dawley rats. Neurosci Lett 1987;23:119–123.
  31. Crum RL, Brown MR: Effects of morphine and opioid peptides on plasma levels of atrial natriuretic peptide. Life Sci 1988;43:851–858.
  32. Chen M, Lee J, Huang BS, Grehin RJ, Malvin RL: Clonidine and morphine increase atrial natriuretic peptide secretion in anesthetized rats. Proc Soc Exp Biol Med 1989;191:299–303.
  33. Baker DG, West SA, Orth DN, Hill KK, Nicholson WE, Ekhator NN, Bruce AB, Wortman MD, Keck PD Jr, Geracioti TD Jr: Cerebrospinal fluid and plasma beta-endorphin in combat veterans with post-traumatic stress disorder. Psychoneuroendocrinology 1997;22:517–529.

    External Resources

  34. Geracioti TD Jr, Baker DG, Ekhator NN, West SA, Hill KK, Bruce AB, Schmidt D, Rounds-Kugler B, Yehuda R, Keck PE Jr, Kasckow JW: CSF norepinephrine concentrations in posttraumatic stress disorder. Am J Psychiatry 2001;158:1227–1230.
  35. Tanabe K, Yamamoto A, Suzuki N, Aksahi Y, Seki A, Samejima H, Oya M, Murabayashi T, Nakayama M, Yokoyama Y, Osada N, Omiya K, Itoh H, Miyake F, Murayama M: Exercise-induced changes in plasma atrial natriuretic peptide and brain natriuretic peptide concentrations in healthy subjects with chronic sleep deprivation. Jpn Circ J 1999;63:447–452.
  36. Kellner M, Wiedemann K: Atrial natriuretic hormone responses to clonidine in patients with panic disorder and in healthy control subjects. Eur J Endocrinol 1997;137:84–85.
  37. Kellner M, Knaudt K, Jahn H, Holsboer F, Wiedemann K: Atrial natriuretic hormone in lactate-induced panic attacks: Mode of release and endocrine and pathophysiological consequences. J Psychiatr Res 1998;32:37–48.
  38. Wiedemann K, Jahn H, Yassouridis A, Kellner M: Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: Preliminary findings. Arch Gen Psychiatry 2001;58:371–377.
  39. Ströhle A, Kellner M, Holsboer F, Wiedemann K: Anxiolytic activity of atrial natriuretic peptide in patients with panic disorder. Am J Psychiatry 2001;158:1514–1526.
  40. Buckley TC, Kaloupek DG: A meta-analytic examination of basal cardiovascular activity in posttraumatic stress disorder. Psychosom Med 2001;63:585–594.
  41. Morimoto A, Nakamori T, Morimoto K, Tan N, Murakami N: The central role of corticotrophin-releasing factor (CRF-41) in psychological stress in rats. J Physiol 1993;460:1–9.
  42. Ku YH, Tan L, Li LS, Ding X: Role of corticotropin-releasing factor and substance P in pressor responses of nuclei controlling emotion and stress. Peptides 1998;19:677–682.

    External Resources

  43. Mason JW, Giller EL, Kosten TR, Harkness L: Elevation of urinary norepinephrine/cortisol ratio in posttraumatic stress disorder. J Nerv Ment Dis 1988;176:498–502.
  44. Coplan JD, Pine D, Papp L, Martinez J, Cooper T, Rosenblum LA, Gorman JM: Uncoupling of the noradrenergic-hypothalamic-pituitary-adrenal axis in panic disorder patients. Neuropsychopharmacology 1995;13:65–73.
  45. Southwick SM, Paige S, Morgan CA 3rd, Bremner JD, Krystal JH, Charney DS: Neurotransmitter alterations in PTSD: Catecholamines and serotonin. Semin Clin Neuropsychiatry 1999;4:242–248.
  46. Tucker P, Smith KL, Marx B, Jones D, Miranda R, Lensgraf J: Fluvoxamine reduces physiologic reactivity to trauma scripts in posttraumatic stress disorder. J Clin Psychopharmacol 2000;20:367–372.
  47. Vasan RS, Larson MG, Leip EP, Evans JC, O’Donnell CJ, Kannel WB, Levy D: Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001;345:1337–1340.
  48. Von Bardeleben U, Stalla GK, Müller OA, Holsboer F: Blunting of ACTH response to human CRH in depressed patients is avoided by metyrapone pretreatment. Biol Psychiatry 1988;24:782–786.
  49. Aguilera G: Regulation of pituitary ACTH secretion during chronic stress. Front Neuroendocrinol 1994;15:321–350.
  50. Yehuda R, Levengood RA, Schmeidler J, Wilson S, Guo LS, Gerber D: Increased pituitary activation following metyrapone administration in posttraumatic stress disorder. Psychoneuroendocrinology 1996;21:1–16.
  51. Ladd CO, Owen MF, Nemeroff CB: Persistent changes in corticotrophin-releasing factor neuronal systems induced by maternal deprivation. Endocrinology 1996;137:1212–1218.
  52. De Bellis MD, Chrousos GP, Dorn LD, Burke L, Hellmers K, Kling MA, Trickett PK, Putnam FW: Hypothalamic-pituitary-adrenal axis dysregulation in sexually abused girls. J Clin Endocrinol Metab 1994;78:249–255.
  53. Kaufman J, Birmaher B, Perel J, Dahl RE, Moreci P, Nelson B, Wells W, Ryan ND: The corticotropin-releasing hormone challenge in depressed abused, depressed nonabused, and normal control children. Biol Psychiatry 1997;42:669–679.
  54. Heim C, Newport DJ, Bonsall R, Miller AH, Nemeroff CB: Altered pituitary-adrenal axis responses to provocative challenge tests in adult survivors of childhood abuse. Am J Psychiatry 2001;158:575–581.
  55. Kellner M, Yassouridis A, Hua Y, Wendrich M, Jahn H, Wiedemann K: Intravenous C-type natriuretic peptide augments behavioral and endocrine effects of cholecystokinin tetrapeptide in healthy men. J Psychiatr Res 2002;36:1–6.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50